Verus Capital Partners LLC Has $539,000 Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Verus Capital Partners LLC raised its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,032 shares of the medical equipment provider’s stock after acquiring an additional 38 shares during the period. Verus Capital Partners LLC’s holdings in Intuitive Surgical were worth $539,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Berbice Capital Management LLC acquired a new position in Intuitive Surgical in the fourth quarter valued at about $26,000. BankPlus Trust Department bought a new position in Intuitive Surgical in the 4th quarter valued at about $28,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Intuitive Surgical in the 3rd quarter valued at approximately $33,000. Decker Retirement Planning Inc. bought a new stake in shares of Intuitive Surgical during the 4th quarter worth approximately $36,000. Finally, Capital Performance Advisors LLP acquired a new stake in shares of Intuitive Surgical during the 3rd quarter worth approximately $38,000. 83.64% of the stock is currently owned by institutional investors.

Insider Activity at Intuitive Surgical

In other news, CFO Jamie Samath sold 270 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $540.15, for a total value of $145,840.50. Following the sale, the chief financial officer now directly owns 8,757 shares of the company’s stock, valued at approximately $4,730,093.55. This represents a 2.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Amal M. Johnson sold 4,635 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the sale, the director now owns 12,275 shares of the company’s stock, valued at approximately $6,955,015. This trade represents a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,077 shares of company stock worth $4,620,025 over the last ninety days. Insiders own 0.80% of the company’s stock.

Wall Street Analyst Weigh In

ISRG has been the subject of several recent analyst reports. Piper Sandler restated an “overweight” rating and set a $670.00 target price (up from $538.00) on shares of Intuitive Surgical in a research note on Friday, January 24th. Royal Bank of Canada upped their price objective on Intuitive Surgical from $611.00 to $641.00 in a research report on Monday, January 27th. Citigroup lifted their target price on Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Stifel Nicolaus increased their target price on shares of Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Finally, Evercore ISI lifted their price target on shares of Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Trading Up 1.7 %

Shares of ISRG stock opened at $573.15 on Friday. Intuitive Surgical, Inc. has a 1-year low of $364.17 and a 1-year high of $616.00. The stock has a market cap of $204.14 billion, a price-to-earnings ratio of 89.42, a PEG ratio of 5.85 and a beta of 1.39. The stock has a 50-day moving average of $569.87 and a 200-day moving average of $528.64.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.